UNSPSC 51132219: Acetaminophen/pamabrom

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132219 Acetaminophen/pamabrom is a Commodity code, but the recent state and local opportunities posted under it do not align with its nominal scope. The three most recent solicitations—from Seminole County, Florida; Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—center on naloxone and drug deactivation systems, therapeutic pharmacy initiatives with direct-to-manufacturer contracting, and generic multi-source pharmaceuticals and over-the-counter products respectively. The code shows minimal recent activity relevant to acetaminophen/pamabrom specifically, and the opportunities tagged to it reflect broader pharmaceutical procurement rather than this single active ingredient formulation.

The issuing bodies span county health departments, state health agencies, and multistate cooperative purchasing vehicles. Seminole County, Florida posted an IFB (Solicitation IFB60459723LAS) on June 30, 2026, due July 26, 2023, for naloxone and drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, exploring direct-to-manufacturer prescription programs; and MMCAP, administered by the Minnesota Department of Administration, released an RFP (S1070000015802) posted January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. The mismatch between the code's stated product and the opportunities actually solicited suggests that state and local procurement offices may be using this code as a catch-all for pharmaceutical sourcing rather than as a precise descriptor of acetaminophen/pamabrom procurement.